Erratum: Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community (British Journal of General Practice (2012) DOI:10.3399/bjgp12X654588);Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community

British Journal of General Practice

Volumn 62, Issue 602, 2012, Pages 406-

  Sheron, Nick ^a   Moore, Mike ^c   Ansett, Stacey ^a   Parsons, Camille ^b   Bateman, Adrian ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c Aldermoor Health Centre   (United Kingdom)

Author keywords

Cirrhosis; Diagnosis; Early diagnosis; Liver diseases; Liver fibrosis; Primary care

Indexed keywords

HYALURONIC ACID; PROCOLLAGEN; PROCOLLAGEN 3 N TERMINAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ARTICLE; ASCITES; BLOOD ANALYSIS; COHORT ANALYSIS; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MODIFIED VERSION SOUTHAMPTON TRAFFIC LIGHT ALGORITHM; PATIENT REFERRAL; SOUTHAMPTON TRAFFIC LIGHT ALGORITHM; SURVIVAL; THROMBOCYTE COUNT; VARICOSIS;

EID: 84865810792     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp13X670912     Document Type: Erratum

References (24)

1. Jewell J, Sheron N. Trends in European liver death rates: implications for alcohol policy. Clin Med 2010; 10(3): 259-263.
2. British Association for the Study of the Liver (BASL), British Society of Gastroenterology (BSG) (Liver Section). A time to act: improving liver health and outcomes in liver disease. National Plan for Liver Services UK 2009. http://eprints.soton.ac.uk/194669/1/National-Liver-Plan-2009.pdf (accessed 20 Jul 2012).
3. Roberts SE, Goldacre MJ, Yeates D. Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 2005; 54(11): 1615-1621.
4. Verrill C, Smith S, Sheron N. Are the opportunities to prevent alcohol related liver deaths in the UK in primary or secondary care? A retrospective clinical review and prospective interview study. Subst Abuse Treat Prev Policy 2006; 1: 16.
5. Sheron N, Moore M, Roderick W, et al. OP01 Alcohol and liver disease detection study ALDDeS: early results and implications. Gut 2011; 59(suppl 2): 1.
6. Leroy V, Halfon P, Bacq Y, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41(16-17): 1368-1376.
7. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43(8): 617-649.
8. Forestier J, Dumortier J, Guillaud O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010; 22(5): 532-540.
9. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010; 15(4): 617-631.
10. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53(3): 726-736.
11. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49(1): 7-18.
12. Efron B. Estimating the error rate of a prediction rule: some improvements on cross-validation. J Am Stat Assoc 1983; 78: 316-331.
13. Efron B, Tibshirani R. Improvements on cross-validation: the 632+ bootstrap method. J Am Stat Assoc 1997; 92: 548-560.
14. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.
15. Sheron N, Moore M, Roderick P, et al. ALDDeS Alcohol and Liver Disease Detection Study. Gut 2010; 59(Suppl 2): A1.
16. Willis BH. Spectrum bias - why clinicians need to be cautious when applying diagnostic test studies. Fam Pract 2008; 25(5): 390-396.
17. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy. J Hepatol 2011; 54(4): 650-659.
18. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010; 15(4): 617-631.
19. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44(3): 214-219.
20. Estep JM, Birerdinc A, Younossi Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med 2010; 10(2): 166-172.
21. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52(10): 1887-1896.
22. Naveau S, Gaude G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49(1): 97-105.
23. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59(9): 1245-1251.
24. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36(4 Pt 1): 986-992.